Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).

Abstract: Provided is a method for the high expression of a recombinant human serum albumin, characterized in comprising the step of co-expressing: (a) a human serum albumin gene, and (b) one or more rHSA expression promoting factor genes in a yeast host cell.

Abstract: The present disclosure provides a cross-blockchain data access method, apparatus and system, and a computer readable medium. The method comprises: sending an authorizing blockchain apparatus a block data request carrying a requesting blockchain apparatus identifier and authorization information, so that the authorizing blockchain apparatus verifies whether the authorization information corresponding to locally-stored requesting blockchain apparatus identifier is matched with the authorization information in the block data request; receiving block data sent by the authorizing blockchain apparatus and corresponding to the block data request, the block data being sent after the authorizing blockchain apparatus verifies that the authorization information corresponding to locally-stored requesting blockchain apparatus identifier is matched with the authorization information in the block data request.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: Establishing a connection is disclosed including acquiring an authentication code, sending data including the authentication code to a management server, receiving parameter information sent back by the management server after the management server performed a successful authentication using the data including the authentication code, and establishing, using the parameter information, a channel to a connection server.

Abstract: Event processing associated with a smart device is disclosed, including: receiving an indication of an event detected by a function module associated with a smart device; determining, based at least in part on event registration information, that an event message is to be sent to a cloud device; and sending the event message to the cloud device. Event processing associated with a smart device also includes: receiving an indication of an event detected by a first function module associated with a smart device; determining, based at least in part on event registration information, that a control message is to be sent to a second function module associated with the smart device; and sending the control message to the second function module associated with the smart device.

Abstract: Action processing associated with a cloud device is disclosed, including: in response to a trigger comprising receiving a forwarding instruction from a control device or receiving an event message from a first smart device, sending an action message to a second smart device, wherein the action message comprises at least an action identifier, wherein the action identifier corresponds to a control instruction to be executed at the second smart device; and receiving an action response message from the second smart device, wherein the action response message comprises the action identifier and an action status identifier, wherein the action status identifier is associated with an execution status of the control instruction at the second smart device.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: An frit-sealed device comprising a resistive heating element having an electrically-closed-loop structure and process for frit-sealing a device by using such heating element. The element can be advantageously made of a metal such as Invar® and/or Kovar®. The invention enables hermetic frit sealing with low residual stress in the seal. The invention is particularly advantageous for hermetic sealing of OLED display devices.

Abstract: A mold for shaping glass-based material can include a mold body having a surface, wherein at least a portion of the mold body near the surface comprises at least about 90% by weight nickel and from about 0.2% to about 0.35% by weight manganese; and a nickel oxide layer on the surface of the mold body. The nickel oxide layer has first and second opposing surfaces wherein the first surface of the nickel oxide layer contacts and faces the surface of the mold body and the second surface of the nickel oxide layer includes a plurality of grains. The plurality of grains has an average grain size of about 150 ?m or less.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.

Abstract: A method for identifying an application scenario of a terminal device, where the method includes analyzing an application program running on a terminal device by means of compilation to obtain characteristic data of the application program; and determining, from a scenario characteristic data set according to the characteristic data of the application program, application scenario information corresponding to the characteristic data of the application program, where the scenario characteristic data set includes a correspondence between multiple types of application scenario information and characteristic data of multiple application programs. Because characteristic data of an application program is more likely to be unique in describing a corresponding application scenario, application scenario information corresponding to the characteristic data of the application program is relatively accurate.

Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.

Abstract: A mold for shaping glass can be made by a method that includes providing a mold body having a shaping surface comprising at least about 90% nickel and modifying the composition of the shaping surface of the mold body by exposing the shaping surface to an oxidizing heat treatment. The oxidizing heat treatment may include a ramping heat treatment, a fixed heat treatment, or both the ramping heat treatment and the fixed heat treatment. The ramping heat treatment may include increasing a heating temperature at a rate from about 20° C./hour to about 500° C./hour to a temperature from about 700° C. to about 1000° C. The fixed heat treatment may include holding the heating temperature from about 700° C. to about 1000° C. for a holding time of at least about 5 minutes.

Abstract: A mold for shaping glass-based material can include a mold body having a surface, wherein at least a portion of the mold body near the surface comprises at least about 90% by weight nickel and from about 0.2% to about 0.35% by weight manganese; and a nickel oxide layer on the surface of the mold body. The nickel oxide layer has first and second opposing surfaces wherein the first surface of the nickel oxide layer contacts and faces the surface of the mold body and the second surface of the nickel oxide layer includes a plurality of grains. The plurality of grains has an average grain size of about 150 ?m or less.